Please enable JavaScript or talk to your local administrator to get JavaScript enabled.

Project

bLadder cAncer URine cEll aNalysis

Funder: European Commission

Funding period
EUR 3.1 M
USD 3.5 M
Funding amount
Abstract
Bladder cancer is the 4th most common cancer in men and the 7th in women, with 330,000- 380,000 new cases annually worldwide or more than 150,000 in Europe and is one of the most expensive cancers to manage. Bladder cancer incidence is strongly related to age, with the highest incidence rates being in older men and women. Cystoscopy/cystoscopic biopsy remains the current gold standard diagnostic and monitoring tool. This procedure is highly invasive and expensive - costing up to €1200 per test - and has been reported to miss in the region of 25% of all bladder tumours. As an adjunct to cystoscopy, urine cytology is routinely carried out globally but its deficiencies in terms of poor cancer detection (low sensitivity) are well recognised and reported.

The overall objective of the LAUREN project is to provide a commercial non-invasive in vitro diagnostic that will significantly reduce the management cost of caring for bladder cancer patients, whilst at the same time improving patient comfort and reducing morbidity associated with current invasive procedures. The specific diagnostic is based on the MCM2 + Immunofluorescence biomarker for bladder cancer cells found in urine.The scope of the project is to complete the final development, validation and regulatory activities required to prepare a novel the new diagnostic for the market.

The objectives of the project are to:
PO1 Clinically validate the biomarkers including the addition of Immuno Fluorescence
PO2 Complete development of and validate a single use cell collection device,
PO3 Validate the cell recognition software for regulatory acceptance
PO4 Validate the software of an automated slide analysis system.
PO5 Prepare a complete evidence package to support obtaining a CE Mark and FDA approval for commercialisation
Similar projects All >
Sorted by: Start Date
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
Identification and analysis of early prognostic markers of bladder cancer using generated nanobodies

Russian Science Foundation to Sergei Tillib

 
2020 - 2022
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023

System

Categories
  • FOR (ANZSRC)

    1112 Oncology and Carcinogenesis

  • RCDC

    Aging

  • RCDC

    Bioengineering

  • RCDC

    Cancer

  • RCDC

    Clinical Research

  • RCDC

    Urologic Diseases

  • HRCS HC

    Cancer

  • HRCS RAC

    4.1 Discovery and preclinical testing of markers and technologies

  • HRCS RAC

    4.2 Evaluation of markers and technologies

  • Health Research Areas

    Biomedical

  • Broad Research Areas

    Clinical Medicine and Science